pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
FOUNDAYO · news · pharmadog
← back to FOUNDAYO
News mentioning FOUNDAYO
48
stories
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
13d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
18d
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
21d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
21d
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
21d
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
26d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
27d
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
Aug 26, 26
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
biospace
Aug 25, 26
Lilly takes oral obesity race abroad with UK launch of Foundayo
biospace
Aug 21, 26
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
biospace
Aug 21, 26
How cost and perception could reshape the GLP-1 market
biopharma dive
Aug 19, 26
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
Aug 12, 26
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
Aug 11, 26
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
Aug 10, 26
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
Aug 5, 26
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
Aug 5, 26
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Jul 31, 26
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
← prev
page 1 of 2
next →
